MELA Sciences (MELA) Enters Extended MelaFind Manufacturing Contract with Askion GmbH
Up)
MELA Sciences, Inc. (Nasdaq: MELA) announced that it has entered into an expanded three-year manufacturing agreement with its long-term supplier, Askion GmbH, for the production of the MelaFind handheld device.
MelaFind is the Company's breakthrough non-invasive and objective automated point of care system for use when a dermatologist chooses to obtain additional information for a decision to biopsy clinically atypical pigmented skin lesions with one or more clinical or historical characteristics of melanoma.
The Company is preparing for commercial launch in the U.S. and the European Union, initially in Germany, which remains on track for the first quarter of 2012.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
MelaFind is the Company's breakthrough non-invasive and objective automated point of care system for use when a dermatologist chooses to obtain additional information for a decision to biopsy clinically atypical pigmented skin lesions with one or more clinical or historical characteristics of melanoma.
The Company is preparing for commercial launch in the U.S. and the European Union, initially in Germany, which remains on track for the first quarter of 2012.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- Auxilium (AUXL) Files Suit Against Watson (WPI) Over Testim 1% Gel
- Morning Movers 05/23: (SCHS) (MELA) (PETM) Higher; (DELL) Lower
- Mylan (MYL) Launches Generic Bonviva Tabs (RHHBY) in Italy & the U.K.
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
